Literature DB >> 7030964

Protection in rats immunized with Escherichia coli heat-stable enterotoxin.

F A Klipstein, R F Engert, J D Clements.   

Abstract

Rats immunized with a semipurified preparation of the Escherichia coli heat-stable (ST) enterotoxin conjugated with a protein carrier were protected against challenge with semipurified or purified ST and viable organisms of multiple heterologous serotypes that produce only ST (LT-/ST+), but they were not protected against heal-labile (LT) toxin or viable strains which produce LT either alone (LT+/ST-) or together with ST (LT+/ST+).

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7030964      PMCID： PMC350915          DOI： 10.1128/iai.34.2.637-639.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  15 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Purification and chemical characterization of the heat-stable enterotoxin produced by porcine strains of enterotoxigenic Escherichia coli.

Authors:  J F Alderete; D C Robertson
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

3.  Cell-free synthesis of enterotoxin of E. coli from a cloned gene.

Authors:  R Lathe; P Hirth; M DeWilde; N Harford; J P Lecocq
Journal:  Nature       Date:  1980-04-03       Impact factor: 49.962

4.  Protective effect of active immunization with purified Escherichia coli heat-labile enterotoxin in rats.

Authors:  F A Klipstein; R F Engert
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

5.  Infantile diarrhea produced by heat-stable enterotoxigenic Escherichia coli.

Authors:  R W Ryder; I K Wachsmuth; A E Buxton; D G Evans; H L DuPont; E Mason; F F Barrett
Journal:  N Engl J Med       Date:  1976-10-14       Impact factor: 91.245

6.  Suckling mouse model for detection of heat-stable Escherichia coli enterotoxin: characteristics of the model.

Authors:  R A Giannella
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

7.  Purification and characterization of heat-stable enterotoxin produced by a strain of E. coli pathogenic for man.

Authors:  S J Staples; S E Asher; R A Giannella
Journal:  J Biol Chem       Date:  1980-05-25       Impact factor: 5.157

8.  Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures.

Authors:  J D Clements; R A Finkelstein
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

9.  Diarrhoea associated with heat-stable enterotoxin-producing strains of Escherichia coli.

Authors:  D A Sack; M H Merson; J G Wells; R B Sack; G K Morris
Journal:  Lancet       Date:  1975-08-09       Impact factor: 79.321

10.  Protective effect of immunization with heat-labile enterotoxin in gnotobiotic rats monocontaminated with enterotoxigenic Escherichia coli.

Authors:  F A Klipstein; R F Engert; H B Short
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441
View more
  22 in total

1.  Establishment, Validation, and Application of a New World Primate Model of Enterotoxigenic Escherichia coli Disease for Vaccine Development.

Authors:  Julianne E Rollenhagen; Franca Jones; Eric Hall; Ryan Maves; Gladys Nunez; Nereyda Espinoza; Aisling O'Dowd; Michael G Prouty; Stephen J Savarino
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

Review 2.  Heat-stable enterotoxin of enterotoxigenic Escherichia coli as a vaccine target.

Authors:  Arne Taxt; Rein Aasland; Halvor Sommerfelt; James Nataro; Pål Puntervoll
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

3.  Establishment and Validation of Pathogenic CS17+ and CS19+ Enterotoxigenic Escherichia coli Challenge Models in the New World Primate Aotus nancymaae.

Authors:  Eric R Hall; Aisling O'Dowd; Julianne E Rollenhagen; Nereyda Espinoza; Gladys Nunez; Stephen J Savarino
Journal:  Infect Immun       Date:  2021-02-16       Impact factor: 3.441

Review 4.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

5.  Properties of cross-linked toxoid vaccines made with hyperantigenic forms of synthetic Escherichia coli heat-stable toxin.

Authors:  F A Klipstein; R F Engert; R A Houghten
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

6.  Maternal vaccination with a fimbrial tip adhesin and passive protection of neonatal mice against lethal human enterotoxigenic Escherichia coli challenge.

Authors:  Wilson B Luiz; Juliana F Rodrigues; Joseph H Crabb; Stephen J Savarino; Luis C S Ferreira
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

7.  Molecular mechanism of Escherichia coli H10407 induced diarrhoea and its control through immunomodulatory action of bioactives from Simarouba amara (Aubl.).

Authors:  Hegde Veena; Sandesh K Gowda; Rajeshwara N Achur; Nayaka Boramuthi Thippeswamy
Journal:  J Microbiol       Date:  2021-02-25       Impact factor: 3.422

8.  Properties of synthetically produced Escherichia coli heat-stable enterotoxin.

Authors:  F A Klipstein; R F Engert; R A Houghten
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

9.  Immunization of swine with heat-stable Escherichia coli enterotoxin coupled to a carrier protein does not protect suckling pigs against an Escherichia coli strain that produces heat-stable enterotoxin.

Authors:  H W Moon; A L Baetz; R A Giannella
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

10.  Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.

Authors:  Gregory M Glenn; Christina P Villar; David C Flyer; A Louis Bourgeois; Robin McKenzie; Robert M Lavker; Sarah A Frech
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.